GILD
GILD
NASDAQ · Biotechnology

Gilead Sciences Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks Best Dividend Stocks
$126.34
+0.01 (+0.01%)
As of Jun 30, 9:31 PM ET ·
Financial Highlights (FY 2026)
Revenue
28.84B
Net Income
8.34B
Gross Margin
78.8%
Profit Margin
28.9%
Rev Growth
+2.6%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 78.8% 78.8% 53.5% 53.5%
Operating Margin 34.0% 30.6% -33.3% -35.4%
Profit Margin 28.9% 27.5% -32.6% -32.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 28.84B 28.12B 56.82B 62.77B
Gross Profit 22.74B 22.17B 30.40B 33.58B
Operating Income 9.82B 8.61B -18,927,955,656 -22,233,853,953
Net Income 8.34B 7.31B -18,545,178,243 -20,228,320,493
Gross Margin 78.8% 78.8% 53.5% 53.5%
Operating Margin 34.0% 30.6% -33.3% -35.4%
Profit Margin 28.9% 27.5% -32.6% -32.2%
Rev Growth +2.6% +2.6% -2.6% +18.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 41.15B 41.15B 23.22B 22.16B
Total Equity 37.46B 37.46B 127.95B 131.01B
D/E Ratio 1.10 1.10 0.18 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 10.18B 9.43B -26,008,242,356 -28,250,733,263
Free Cash Flow — — -20,166,967,145 -15,276,791,822